^
Association details:
| Biomarker: | DDR2 S768R |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | erlotinib (EGFR inhibitor) + dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer
Excerpt:
The patient was a 59 year old Caucasian woman...began combination dasatinib and erlotinib therapy on protocol. A restaging CT scan after nearly 2 months indicated tumor shrinkage and the patient experienced improved symptoms (resolved dyspnea and cough) (Figures 5A and 5B).
DOI:
10.1158/2159-8274.CD-11-0005
